Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 12 December, 2013 and appeared in  BG ControlMedical DevicesInsulinGlucose MonitoringIssue 707

Insulin Pumps vs. Multiple Daily Injections (MDI): Which is Better?

Can insulin pumps reduce glycemic variability in type 1 diabetes?...

Advertisement

A new cross-sectional observational cohort study looked at continuous subcutaneous insulin infusion (CSII), aka insulin pump, versus multiple daily injections (MDI) to determine which insulin delivery system resulted in less blood glucose variability in type 1 pediatric diabetes patients. Large variations in blood glucose have been implicated in causing cardiovascular complications which can lead to a number of comorbidities and mortality in diabetics.

This recent study was performed in 48 pediatric type 1 diabetes patients, 22 of whom used an insulin pump while the others used MDI. The patients were followed for 3 days using continuous blood glucose monitoring; blood glucose variability was also assessed in 2 consecutive 24 hour periods by a surrogate marker, F2-isoprostanes and/or urinary prostaglandin F2 excretion. Results showed that standard deviation of mean glucose concentration (p<0.05) and insulin requirements, HDL-cholesterol, the mean of glycemic excursions (p<0.01) were statistically lower in the insulin pump group.

While the study did not specifically look at the impact of insulin pump use vs. MDI on cardiovascular complications, one could assume that limiting glucose variations would have a positive impact on the cardiovascular system. The study was small and the MDI groups were even smaller. Each MDI group had somewhere between 4 - 9 patients who were assigned certain insulins whether that be normal, fast acting, basal and/or a combo of thereof. Further research and longitudinal studies would be of benefit to better assess association of CSII therapy versus MDI therapy and their impact on cardiovascular, co-morbidity, and mortality outcomes.

Practice Pearls:

  • Large variations in plasma glucose have been implicated in causing cardiovascular complications.
  • Patients with type 1 diabetes are significantly more likely to develop cardiovascular disease versus their peers.
  • Using continuous subcutaneous insulin infusion seems to be associated with reduced variations in blood glucose levels versus using multiple daily injections in type 1 diabetes.

Schreiver, C. et al. Glycemic Variability in Pediatric Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections (MDI). Clin Endocrinol. 2013;79(5):641-647 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 12 December, 2013 and appeared in  BG ControlMedical DevicesInsulinGlucose MonitoringIssue 707

Past five issues: Diabetes Clinical Mastery Series Issue 204 | Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014
Peripheral Neuropathy Associated with CV Disease and Stroke in Type 2 Diabetes Patients
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Diabetes Nutrition Recommendations: Obesity and Diabetes Prevention
Judith Wylie-Rosett, EdD, RD

Category: Nutrition
Credits: .5



Search Articles On Diabetes In Control